ArticleCurrent therapeutic research, clinical and experimental2025
Initiation of Type 2 Diabetes Mellitus Medications in the NGHA Healthcare System in Saudi Arabia: Contemporary Trends.
Article in Current therapeutic research, clinical and experimental, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparative effects of metformin and lifestyle therapy on bone metabolism markers: A 6-month pilot, open-label randomized-clinical trial.Aging clinical and experimental research · 2026Trial
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Continuous updates in management guidelines for type 2 diabetes mellitus (T2DM) have affected treatment patterns. In this study, we aimed to identify the prevalence of initiating various antidiabetic medications and analyze differences in patient characteristics based on the type of treatment initiated. Methods: This cross-sectional study used data retrieved from the electronic medical records of the National Guard Health Affairs for all patients diagnosed with T2DM who initiated any antidiabetic therapy between January 2018 and May 2022. Patient data were presented using frequencies, percentages, means, and standard deviations where applicable. The antidiabetic classes investigated include metformin, insulin, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors. Results: In total, 433 patients with T2DM were included in this study, most of whom were females (55.66% vs 44.34%) and obese (61.20%), with a mean age of 53.29 years (SD ± 15.22). Monotherapy was the most commonly initiated approach (66.28%), with insulin being the most prescribed monotherapy (29.10%). The most frequent combination therapy was metformin and sulfonylureas (7.16%). Overall, the most initiated medication was metformin, accounting for 37.12% of all prescriptions. Additionally, there was an increasing trend in prescribing newer medications, such as GLP-1 receptor agonists (8.70%) and SGLT-2 inhibitors (11.11%), for newly diagnosed patients in 2021. Conclusion: The initiation of novel antidiabetic medications has increased over the study period, reflecting recent updates in T2DM management guidelines. However, further understanding of their benefits is required for optimal patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.